CN114456191B - 山药地上部分生育酚衍生物的提取方法和应用 - Google Patents
山药地上部分生育酚衍生物的提取方法和应用 Download PDFInfo
- Publication number
- CN114456191B CN114456191B CN202210071491.3A CN202210071491A CN114456191B CN 114456191 B CN114456191 B CN 114456191B CN 202210071491 A CN202210071491 A CN 202210071491A CN 114456191 B CN114456191 B CN 114456191B
- Authority
- CN
- China
- Prior art keywords
- column chromatography
- compound
- ethanol
- petroleum ether
- yam
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000002722 Dioscorea batatas Nutrition 0.000 title claims abstract description 22
- 240000001811 Dioscorea oppositifolia Species 0.000 title claims abstract description 22
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 title claims abstract description 22
- 235000006536 Dioscorea esculenta Nutrition 0.000 title claims abstract description 21
- 150000003611 tocopherol derivatives Chemical class 0.000 title claims abstract description 17
- 238000000605 extraction Methods 0.000 title claims abstract description 9
- 235000004879 dioscorea Nutrition 0.000 claims abstract description 23
- 239000003472 antidiabetic agent Substances 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 62
- 239000003208 petroleum Substances 0.000 claims description 34
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 20
- 238000004440 column chromatography Methods 0.000 claims description 17
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 16
- 238000010898 silica gel chromatography Methods 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 14
- 229920005654 Sephadex Polymers 0.000 claims description 13
- 239000012507 Sephadex™ Substances 0.000 claims description 13
- 239000012259 ether extract Substances 0.000 claims description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- 239000000469 ethanolic extract Substances 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 11
- 239000011347 resin Substances 0.000 claims description 11
- 229920005989 resin Polymers 0.000 claims description 11
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 claims description 10
- 229940125898 compound 5 Drugs 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 238000001179 sorption measurement Methods 0.000 claims description 7
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 claims description 6
- 229940126214 compound 3 Drugs 0.000 claims description 6
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 5
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 5
- 229940125904 compound 1 Drugs 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 4
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 2
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 abstract description 14
- 108010028144 alpha-Glucosidases Proteins 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 12
- 230000005764 inhibitory process Effects 0.000 abstract description 9
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 abstract description 6
- 229960002632 acarbose Drugs 0.000 abstract description 6
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 abstract description 6
- 244000281702 Dioscorea villosa Species 0.000 description 20
- 239000000243 solution Substances 0.000 description 11
- 206010012601 diabetes mellitus Diseases 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000003463 adsorbent Substances 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- LNZMEOLVTKHUAS-UHFFFAOYSA-N cyclohexane;dichloromethane Chemical compound ClCCl.C1CCCCC1 LNZMEOLVTKHUAS-UHFFFAOYSA-N 0.000 description 4
- 238000004611 spectroscopical analysis Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 3
- 238000004262 preparative liquid chromatography Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 235000000504 Dioscorea villosa Nutrition 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- XSELOQGXDYVVCH-UHFFFAOYSA-N (-)-Tocospirone Natural products CC(C)CCCC(C)CCCC(C)CCCC1(C)CCC2(O1)C(=O)C(=C(C)C(=O)C2(C)O)C XSELOQGXDYVVCH-UHFFFAOYSA-N 0.000 description 1
- IFBHRQDFSNCLOZ-IIRVCBMXSA-N 4-nitrophenyl-α-d-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-IIRVCBMXSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000005903 Dioscorea Nutrition 0.000 description 1
- 241000234272 Dioscoreaceae Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- 229940066595 beta tocopherol Drugs 0.000 description 1
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N beta-Tocopherol Natural products OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 1
- 235000021257 carbohydrate digestion Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011542 limb amputation Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 239000011590 β-tocopherol Substances 0.000 description 1
- 235000007680 β-tocopherol Nutrition 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
- C07C50/28—Quinones containing groups having oxygen atoms singly bound to carbon atoms with monocyclic quinoid structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种山药地上部分生育酚衍生物的提取方法和应用,该方法将山药地上部分粗粉用乙醇渗漉提取并浓缩,提取物用有机溶剂萃取,然后经大孔吸附树脂、硅胶、葡聚糖糖凝胶等柱层析分离得到五种生育酚衍生物。本发明从山药地上部分中制备得到的五种生育酚衍生物对α‑葡萄糖苷酶均有显著的抑制活性,在相同条件下均优于降血糖药阿卡波糖的活性。
Description
技术领域
本发明属于山药地上部分有效成分的分离及应用技术领域,具体涉及一种山药地上部分生育酚衍生物的提取方法及应用。
背景技术
由于人民生活水平的提高、饮食结构的改变以及少动多坐的生活方式等诸多因素,全球糖尿病发病率增长迅速,糖尿病已经成为继肿瘤、心血管病变之后第三大严重威胁人类健康的慢性疾病。此外,糖尿病是心血管疾病、失明、肾衰竭、中风和四肢截肢的主要原因。我国糖尿病的患病率为11.6%,远远超过世界平均水平,其中约90%的糖尿病患者被诊断为II型糖尿病。糖尿病的发病过程中最先出现的症状往往是餐后高血糖,即糖尿病的早期征兆,特别是II型糖尿病病人,餐后高血糖不仅极易诱发各种并发症,还会极大地提高糖尿病的死亡率。所以,降低餐后血糖是预防糖尿病、减少并发症和降低死亡率的重要措施之一。α-葡萄糖苷酶是碳水化合物消化过程的一种关键酶,能催化膳食碳水化合物释放葡萄糖,从而提高血糖水平,它是控制餐后血糖的主要靶酶之一。抑制α-葡萄糖苷酶的活性就能延缓食物中碳水化合物的分解,从而减少葡萄糖的摄入,达到抑制餐后血糖升高的目的,α-葡萄糖苷酶抑制剂的研发对II型糖尿病的治疗有重要意义。目前临床上的此类药物有阿卡波糖、伏格列波糖和米格列醇,均存在胃肠道副作用。现有的α-葡萄糖苷酶抑制剂种类较少,并伴有肠道副作用,因此人们仍不断致力于开发新型α-葡萄糖苷酶抑制剂。
山药为薯蓣科薯蓣(Disocorea opposita Thunb.)的干燥根茎,具有补脾养肺,固肾益精之功效,临床上广泛用于治疗消渴症、慢性腹泻和虚劳咳嗽等症状,是我国传统的药食同源中药之一,自古以河南焦作(古怀庆府)所产最为地道,故称“怀山药”,为著名的“四大怀药”之一。2006年河南省武陟县获批山药GAP种植基地,解决了野生山药资源短缺,资源可持续利用发展等问题。山药以地下根茎入药,地上部分常作为废弃物被遗弃,导致资源的极大浪费。目前对于山药的研究主要集中于地下根茎(入药部位)的研究,药理研究显示其具有降血糖、降血脂、抗氧化和抗肿瘤等活性。然而对于山药地上部分的研究非常少,造成资源的巨大浪费,从山药地上部分挖掘天然α-葡萄糖苷酶抑制剂具有重要的意义。
发明内容
本发明解决的技术问题是提供了一种山药地上部分生育酚衍生物的提取方法和应用,该方法将山药地上部分粗粉用乙醇渗漉提取并浓缩,提取物用有机溶剂萃取,然后经大孔吸附树脂、硅胶、葡聚糖糖凝胶柱层析或制备液相色谱仪分离得到山药地上部分生育酚衍生物,分离提取的五种生育酚衍生物对α-葡萄糖苷酶均具有显著的抑制作用。
本发明为解决上述技术问题采用如下技术方案,山药地上部分生育酚衍生物的提取方法,其特征在于具体步骤为:
步骤S1:将阴干的山药地上部分粉碎后用体积分数90%-95%乙醇渗漉提取,合并提取液,减压浓缩得到山药地上部分乙醇提取物,将该山药地上部分乙醇提取物悬浮于蒸馏水中,用石油醚萃取,收集石油醚萃取液,并减压浓缩得到石油醚萃取物;
步骤S2:将步骤S1得到的石油醚萃取物经大孔吸附树脂柱层析,依次用体积分数80%和90%乙醇洗脱,收集体积分数90%乙醇洗脱液减压浓缩得到90%乙醇洗脱产物,将90%乙醇洗脱产物经常压硅胶柱色谱分离,以体积比为50:1、15:1和10:1的石油醚-丙酮溶剂系统依次进行洗脱,经TLC鉴定合并相同组分得到初始目标组分Fr.1-Fr.3,将初始目标组分Fr.3继续经常压硅胶柱色谱分离,以体积比为3.5:1、2:1、1:1和1:2的环己烷-二氯甲烷溶剂系统依次进行洗脱,经TLC鉴定合并相同组分得到中间目标组分Fr.3A-Fr.3D;
步骤S3:将步骤S2得到的中间目标组分Fr.3C经葡聚糖凝胶柱色谱和制备液相色谱仪Pre-HPLC纯化得到化合物1,其中葡聚糖凝胶柱色谱的洗脱液为体积比为1:1的二氯甲烷-甲醇溶剂系统,制备液相色谱仪Pre-HPLC的流动相为体积比为95:5的乙腈-水溶剂系统,该化合物1的结构式为
步骤S4:将步骤S2得到的中间目标组分Fr.3D经常压硅胶柱色谱分离,以体积比为200:1、100:1、70:1、60:1、50:1、40:1、30:1、20:1和15:1的石油醚-丙酮溶剂系统依次进行洗脱,经TLC鉴定合并相同组分得到中间目标组分Fr.3Da-Fr.3Di,将中间目标组分Fr.3Db经制备液相色谱仪Pre-HPLC分离,以乙腈为流动相得到化合物2和化合物3,其中化合物2的结构式为化合物3的结构式为将中间目标组分Fr.3Dc经制备液相色谱仪Pre-HPLC分离,以体积比为96:4的乙腈-水溶剂系统为流动相得到化合物4,该化合物4的结构式为将中间目标组分Fr.3Dh经葡聚糖凝胶柱色谱和制备液相色谱仪Pre-HPLC纯化得到化合物5,其中葡聚糖凝胶柱色谱的洗脱液为体积比为1:1的二氯甲烷-甲醇溶剂系统,制备液相色谱仪Pre-HPLC的流动相为乙腈,该化合物5的结构式为
进一步优选,步骤S2中所述大孔吸附树脂为Diaion HP-20型大孔吸附树脂;步骤S3和S4中所述葡聚糖凝胶均为Sephadex LH-20型葡聚糖凝胶;步骤S3和S4中所述制备液相色谱仪Pre-HPLC所用色谱柱均为YMC ODS-A色谱柱。
本发明所述的山药地上部分生育酚衍生物在制备降血糖药物或辅助降血糖保健品中的应用。
本发明所述的山药地上部分生育酚衍生物在制备α-葡萄糖苷酶抑制剂类药物中的应用。
本发明通过体外α-葡萄糖苷酶抑制活性研究发现山药地上部分提取的五种生育酚衍生物对α-葡萄糖苷酶均有显著的抑制作用,其IC50分别为8.46±0.92μM、8.12±0.72μM、10.63±0.45μM、6.06±0.03μM和6.67±0.90μM,明显强于阳性对照药阿卡波糖的活性(IC50为149.33±7.48μM),并且对α-葡萄糖苷酶的抑制率均呈剂量依赖性。
附图说明
图1为实施例中山药地上部分生育酚衍生物对α-葡萄糖苷酶抑制率随药物浓度的变化图,其中1-化合物1,2-化合物2,3-化合物3,4-化合物4,5-化合物5。
具体实施方式
以下通过实施例对本发明的上述内容做进一步详细说明,但不应该将此理解为本发明上述主题的范围仅限于以下的实施例,凡基于本发明上述内容实现的技术均属于本发明的范围。
实施例1
化合物1的制备
取阴干的山药地上部分17Kg,粉碎后用体积分数95%乙醇渗漉提取,合并提取液,减压浓缩得到山药地上部分乙醇提取物1.97Kg,将该山药地上部分乙醇提取物悬浮于2倍量的蒸馏水中,用6倍量石油醚萃取,收集石油醚萃取液,并减压浓缩得到石油醚萃取物544.8g。将石油醚萃取物经Diaion HP-20型大孔吸附树脂柱层析,依次用体积分数80%和90%乙醇洗脱,收集体积分数90%乙醇洗脱液减压浓缩得到体积分数90%乙醇洗脱产物223.1g;将体积分数90%乙醇洗脱产物经常压硅胶柱色谱分离,以石油醚-丙酮(体积比为50:1、15:1和10:1)溶剂系统洗脱,经TLC鉴定合并相同组分得到3个组分(Fr.1-Fr.3);将组分Fr.3继续经常压硅胶柱色谱分离,以环己烷-二氯甲烷(体积比为3.5:1、2:1、1:1和1:2)溶剂系统洗脱,经TLC鉴定合并相同组分得到4个组分(Fr.3A-Fr.3D);Fr.3C经SephadexLH-20葡聚糖凝胶柱色谱(体积比为1:1的二氯甲烷-甲醇溶剂系统洗脱)和制备液相色谱仪Pre-HPLC(流动相:体积比为95:5的乙腈-水溶剂系统)纯化得到化合物1(5.5mg),该化合物1的结构式为:
化合物1的波谱数据:α-tocospirosA(1):ESIMS m/z:485[M+Na+];1H NMR(400MHz,CDCl3):δH4.73(1H,s,4-OH),2.43(1H,dt,J=12.4,7.1Hz,Hβ-7),2.02(3H,s,H3-3a),1.91(1H,dt,J=11.5,7.1Hz,Hα-8),1.84(3H,s,H3-6a),1.83(3H,s,H3-5a),1.79(1H,dt,J=12.4,7.1Hz,Hα-7),1.70(1H,dt,J=11.5,7.1Hz,Hβ-8),1.61(2H,dd,J=9.0,6.9Hz,H2-10),1.05(3H,s,H3-9a),0.86(6H,d,J=6.7Hz,H3-21aand H3-22)0.85(3H,d,J=6.7Hz,H3-13a),0.84(3H,d,J=6.7Hz,H3-17a).13C NMR(100MHz,CDCl3)δC207.3(C-3),205.1(C-1),163.2(C-5),139.5(C-6),92.3(C-2),89.2(C-4),87.2(C-9),41.6(C-10),39.5(C-20),37.7(C-12),37.63(C-14),37.62(C-16),37.4(C-18),36.3(C-8),33.0(C-13),32.95(C-7),32.9(C-17),28.1(C-21),25.6(C-9a),25.0(C-15),24.95(C-3a),24.6(C-19),22.9(C-22),22.8(C-21a),22.6(C-11),19.9(C-13a),19.8(C-17a),12.0(C-5a),8.9(C-6a)。
实施例2
化合物2和化合物3的制备
取阴干的山药地上部分17Kg,粉碎后用体积分数95%乙醇渗漉提取,合并提取液,减压浓缩得到山药地上部分乙醇提取物1.97Kg,将该山药地上部分乙醇提取物悬浮于2倍量的蒸馏水中,用6倍量石油醚萃取,收集石油醚萃取液,并减压浓缩得到石油醚萃取物544.8g。将石油醚萃取物经Diaion HP-20型大孔吸附树脂柱层析,依次用体积分数80%和90%乙醇洗脱,收集体积分数90%乙醇洗脱液减压浓缩得到体积分数90%乙醇洗脱产物223.1g;将体积分数90%乙醇洗脱产物经常压硅胶柱色谱分离,以石油醚-丙酮(体积比为50:1、15:1和10:1)溶剂系统洗脱,经TLC鉴定合并相同组分得到3个组分(Fr.1-Fr.3);将组分Fr.3继续经常压硅胶柱色谱分离,以环己烷-二氯甲烷(体积比为3.5:1、2:1、1:1和1:2)溶剂系统洗脱,经TLC鉴定合并相同组分得到4个组分(Fr.3A-Fr.3D);Fr.3D经常压硅胶柱色谱分离,以石油醚-丙酮(体积比为200:1、100:1、70:1、60:1、50:1、40:1、30:1、20:1和15:1)溶剂系统洗脱,经TLC鉴定合并相同组分得到9个组分(Fr.3Da-Fr.3Di);Fr.3Db经制备液相色谱仪Pre-HPLC分离(乙腈为流动相)得到化合物2(6.1mg)和化合物3(4.9mg),其中化合物2的结构式为:
化合物3的结构式为:
化合物2的波谱数据:5-formyl-γ-tocopherol(2):ESIMS m/z:467[M+Na+];1HNMR(400MHz,CDCl3):δH 12.11(1H,s,6-OH),10.20(1H,s,H-5a),3.03(2H,t,J=6.8Hz,H2-4),1.83(2H,m,H2-3),2.17(3H,s,H3-7a),2.15(3H,s,H3-8a),1.26(3H,s,H3-2a),0.86(6H,d,J=6.6Hz,H3-22a and H3-23),0.85(3H,d,J=6.6Hz,H3-14a),0.84(3H,d,J=6.6Hz,H3-18a).13C NMR(100MHz,CDCl3)δC 194.0(C-5a),155.8(C-6),144.0(C-9),138.5(C-8),124.2(C-10),117.6(C-7),114.5(C-5),75.2(C-2),39.5(C-11),39.4(C-21),37.5(C-13),37.4(C-15),37.4(C-17),37.3(C-19),32.8(C-14),32.7(C-18),30.8(C-3),28.0(C-22),24.8(C-20),24.5(C-16),23.7(C-2a),22.8(C-22a),22.7(C-23),21.0(C-12),19.8(C-14a),19.7(C-18a),18.4(C-4),13.2(C-8a),11.1(C-7a)。
化合物3的波谱数据:7-formyl-β-tocopherol(3):ESIMS m/z:467[M+Na+];1H NMR(400MHz,CDCl3):δH 11.83(1H,s,6-OH),10.29(1H,s,H-7a),2.67(2H,t,J=6.9Hz,H2-4),1.82(2H,m,H2-3),2.41(3H,s,H3-8a),2.11(3H,s,H3-5a),1.25(3H,s,H3-2a),0.86(6H,d,J=6.6Hz,H3-22a and H3-23),0.85(3H,d,J=6.6Hz,H3-14a),0.83(3H,d,J=6.6Hz,H3-18a).13C NMR(100MHz,CDCl3)δC 195.6(C-7a),154.2(C-6),144.2(C-9),132.3(C-10),125.6(C-8),121.8(C-5),117.0(C-7),75.3(C-2),39.7(C-11),39.5(C-21),37.6(C-13),37.5(C-15),37.5(C-17),37.4(C-19),32.9(C-14),32.8(C-18),31.2(C-3),28.1(C-22),25.0(C-20),24.6(C-16),24.0(C-2a),22.9(C-22a),22.8(C-23),22.0(C-4),21.1(C-12),19.9(C-14a),19.8(C-18a),14.3(C-8a),10.3(C-5a)。
实施例3
化合物4的制备
取阴干的山药地上部分17Kg,粉碎后用体积分数95%乙醇渗漉提取,合并提取液,减压浓缩得到山药地上部分乙醇提取物1.97Kg,将该山药地上部分乙醇提取物悬浮于2倍量的蒸馏水中,用6倍量石油醚萃取,收集石油醚萃取液,并减压浓缩得到石油醚萃取物544.8g。将石油醚萃取物经Diaion HP-20型大孔吸附树脂柱层析,依次用体积分数80%和90%乙醇洗脱,收集体积分数90%乙醇洗脱液减压浓缩得到体积分数90%乙醇洗脱产物223.1g;将体积分数90%乙醇洗脱产物经常压硅胶柱色谱分离,以石油醚-丙酮(体积比为50:1、15:1和10:1)溶剂系统洗脱,经TLC鉴定合并相同组分得到3个组分(Fr.1-Fr.3);将组分Fr.3继续经常压硅胶柱色谱分离,以环己烷-二氯甲烷(体积比为3.5:1、2:1、1:1和1:2)溶剂系统洗脱,经TLC鉴定合并相同组分得到4个组分(Fr.3A-Fr.3D);Fr.3D经常压硅胶柱色谱分离,以石油醚-丙酮(体积比为200:1、100:1、70:1、60:1、50:1、40:1、30:1、20:1和15:1)溶剂系统洗脱,经TLC鉴定合并相同组分得到9个组分(Fr.3Da-Fr.3Di);Fr.3Dc经制备液相色谱仪Pre-HPLC纯化,以体积比为96:4的乙腈-水溶剂系统为流动相得到化合物4(6.5mg),该化合物4的结构式为:
化合物4的波谱数据:(-)-α-tocospirone(4):ESIMS m/z:485[M+Na+];1H NMR(400MHz,CDCl3):δH 3.83(1H,s,3-OH),2.064(3H,s,H3-6a),2.058(3H,s,H3-5a),2.03(1H,m,Hb-7),1.94(1H,m,Hb-8),1.70(1H,m,Ha-7),1.66(1H,m,Hb-10),1.62(1H,m,Ha-8),1.59(1H,m,Ha-10),1.37(3H,s,H3-3a),1.33(3H,s,H3-9a),0.86(3H,d,J=6.7Hz,H3-22),0.85(3H,d,J=6.7Hz,H3-21a),0.84(3H,d,J=6.7Hz,H3-13a),0.83(3H,d,J=6.7Hz,H3-17a).13C NMR(100MHz,CDCl3)δC 201.9(C-4),199.0(C-1),147.1(C-6),142.2(C-5),93.5(C-2),87.2(C-9),81.4(C-3),41.5(C-10),39.5(C-20),37.7(C-12),37.6(C-14),37.5(C-16),37.4(C-18),36.6(C-8),32.94(C-13),32.87(C-17),32.2(C-7),28.1(C-21),25.9(C-9a),25.0(C-15),24.6(C-19),24.4(C-3a),22.9(C-22),22.8(C-21a),22.5(C-11),19.91(C-13a),19.87(C-17a),13.6(C-6a),13.2(C-5a)。
实施例4
化合物5的制备
取阴干的山药地上部分17Kg,粉碎后用体积分数95%乙醇渗漉提取,合并提取液,减压浓缩得到山药地上部分乙醇提取物1.97Kg,将该山药地上部分乙醇提取物悬浮于2倍量的蒸馏水中,用6倍量石油醚萃取,收集石油醚萃取液,并减压浓缩得到石油醚萃取物544.8g。将石油醚萃取物经Diaion HP-20型大孔吸附树脂柱层析,依次用体积分数80%和90%乙醇洗脱,收集体积分数90%乙醇洗脱液减压浓缩得到体积分数90%乙醇洗脱产物223.1g;将体积分数90%乙醇洗脱产物经常压硅胶柱色谱分离,以石油醚-丙酮(体积比为50:1、15:1和10:1)溶剂系统洗脱,经TLC鉴定合并相同组分得到3个组分(Fr.1-Fr.3);将组分Fr.3继续经常压硅胶柱色谱分离,以环己烷-二氯甲烷(体积比为3.5:1、2:1、1:1和1:2)溶剂系统洗脱,经TLC鉴定合并相同组分得到4个组分(Fr.3A-Fr.3D);Fr.3D经常压硅胶柱色谱分离,以石油醚-丙酮(体积比为200:1、100:1、70:1、60:1、50:1、40:1、30:1、20:1和15:1)溶剂系统洗脱,经TLC鉴定合并相同组分得到9个组分(Fr.3Da-Fr.3Di);Fr.3Dh经Sephadex LH-20葡聚糖凝胶柱色谱(体积比为1:1的二氯甲烷-甲醇溶剂系统洗脱)和制备液相色谱仪Pre-HPLC(流动相:乙腈)纯化得到化合物5(4.5mg),该化合物5的结构式为:
化合物5的波谱数据:α-tocopherylquinone(5):ESIMS m/z:592[M+Na+];1H NMR(400MHz,CDCl3):δH 2.54(2H,m,H2-7),2.03(3H,s,H3-3a),2.01(6H,s,H3-5a and H3-6a),1.23(3H,s,H3-9a),0.86(6H,d,J=6.7Hz,H3-21a and H3-22)0.85(3H,d,J=6.7Hz,H3-13a),0.84(3H,d,J=6.7Hz,H3-17a).13C NMR(100MHz,CDCl3)δC 187.9(C-4),187.4(C-1),144.6(C-2),140.7(C-6),140.6(C-5),140.3(C-3),72.8(C-9),42.4(C-10),40.4(C-8),39.5(C-20),37.7(C-12),37.6(C-14),37.6(C-16),37.4(C-18),33.0(C-13),32.9(C-17),28.1(C-21),26.7(C-9a),25.0(C-19),24.6(C-15),22.9(C-22),22.8(C-21a),21.6(C-11),21.5(C-7),19.90(C-13a),19.85(C-17a),12.54(C-6a),12.46(C-5a),12.1(C-3a)。
实施例5
本实施例为上述实施例提取的化合物1-5对α-葡萄糖苷酶的抑制活性测试。
方法:微孔板法。
仪器:酶标仪,恒温培养箱,分析天平,各种型号移液枪。
试剂:α-葡萄糖苷酶、4-硝基苯-α-D-吡喃葡萄糖苷、阿卡波糖、磷酸盐缓冲液和二甲基亚砜、碳酸钠。
测试方法:取96孔板,每孔加入2.0mmol/L的PNPG溶液(PBS溶解)80μL,再分别加入10μL不同浓度样品溶液(DMSO溶解),以DMSO为空白对照组,每组设3个平行孔,在恒温培养箱中放置10min,在酶标仪405nm下测定背景组吸光度(A值)。然后再加入10μL 1U/mLα-葡萄糖苷酶溶液(PBS溶解),置于恒温培养箱中,在37℃下恒温孵育30min,加入浓度为0.2mM的Na2CO380μL,405nm下测定试验组吸光度(A值)。抑制率(%)用以下公式计算:
抑制率(%)=(ΔA空白-ΔA样品)/ΔA空白×100%
ΔA空白为空白组酶与底物反应后A值-背景A值;
ΔA样品为样品组酶与底物反应后A值-背景A值。
化合物1-5对α-葡萄糖苷酶的抑制活性结果如下(表1):
表1化合物1-5对α-葡萄糖苷酶的抑制活性
从表1可以看出,实施例1-4提取的化合物1-5对α-葡萄糖苷酶的抑制活性均强于阳性对照药阿卡波糖的活性,远优于阳性对照药阿卡波糖的活性,其中化合物4的活性最强。
以上显示和描述了本发明的基本原理,主要特征和优点,在不脱离本发明精神和范围的前提下,本发明还有各种变化和改进,这些变化和改进都落入要求保护的本发明的范围。
Claims (4)
1.山药地上部分生育酚衍生物的提取方法,其特征在于具体步骤为:
步骤S1:将阴干的山药地上部分粉碎后用体积分数90%-95%乙醇渗漉提取,合并提取液,减压浓缩得到山药地上部分乙醇提取物,将该山药地上部分乙醇提取物悬浮于蒸馏水中,用石油醚萃取,收集石油醚萃取液,并减压浓缩得到石油醚萃取物;
步骤S2:将步骤S1得到的石油醚萃取物经大孔吸附树脂柱层析,依次用体积分数80%和90%乙醇洗脱,收集体积分数90%乙醇洗脱液减压浓缩得到90%乙醇洗脱产物,将90%乙醇洗脱产物经常压硅胶柱色谱分离,以体积比为50:1、15:1和10:1的石油醚-丙酮溶剂系统依次进行洗脱,经TLC鉴定合并相同组分得到初始目标组分Fr.1-Fr.3,将初始目标组分Fr.3继续经常压硅胶柱色谱分离,以体积比为3.5:1、2:1、1:1和1:2的环己烷-二氯甲烷溶剂系统依次进行洗脱,经TLC鉴定合并相同组分得到中间目标组分Fr.3A-Fr.3D;
步骤S3:将步骤S2得到的中间目标组分Fr.3C经葡聚糖凝胶柱色谱和制备液相色谱仪Pre-HPLC纯化得到化合物1,其中葡聚糖凝胶柱色谱的洗脱液为体积比为1:1的二氯甲烷-甲醇溶剂系统,制备液相色谱仪Pre-HPLC的流动相为体积比为95:5的乙腈-水溶剂系统,该化合物1的结构式为
步骤S4:将步骤S2得到的中间目标组分Fr.3D经常压硅胶柱色谱分离,以体积比为200:1、100:1、70:1、60:1、50:1、40:1、30:1、20:1和15:1的石油醚-丙酮溶剂系统依次进行洗脱,经TLC鉴定合并相同组分得到中间目标组分Fr.3Da-Fr.3Di,将中间目标组分Fr.3Db经制备液相色谱仪Pre-HPLC分离,以乙腈为流动相得到化合物2和化合物3,其中化合物2的结构式为化合物3的结构式为将中间目标组分Fr.3Dc经制备液相色谱仪Pre-HPLC分离,以体积比为96:4的乙腈-水溶剂系统为流动相得到化合物4,该化合物4的结构式为将中间目标组分Fr.3Dh经葡聚糖凝胶柱色谱和制备液相色谱仪Pre-HPLC纯化得到化合物5,其中葡聚糖凝胶柱色谱的洗脱液为体积比为1:1的二氯甲烷-甲醇溶剂系统,制备液相色谱仪Pre-HPLC的流动相为乙腈,该化合物5的结构式为
2.根据权利要求1所述的山药地上部分生育酚衍生物的提取方法,其特征在于:步骤S2中所述大孔吸附树脂为Diaion HP-20型大孔吸附树脂;步骤S3和S4中所述葡聚糖凝胶均为Sephadex LH-20型葡聚糖凝胶;步骤S3和S4中所述制备液相色谱仪Pre-HPLC所用色谱柱均为YMC ODS-A色谱柱。
3.根据权利要求1或2所述的提取方法制得的山药地上部分生育酚衍生物在制备降血糖药物或辅助降血糖保健品中的应用。
4.根据权利要求1或2所述的提取方法制得的山药地上部分生育酚衍生物在制备α-葡萄糖苷酶抑制剂类药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210071491.3A CN114456191B (zh) | 2022-03-29 | 2022-03-29 | 山药地上部分生育酚衍生物的提取方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210071491.3A CN114456191B (zh) | 2022-03-29 | 2022-03-29 | 山药地上部分生育酚衍生物的提取方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114456191A CN114456191A (zh) | 2022-05-10 |
CN114456191B true CN114456191B (zh) | 2023-04-11 |
Family
ID=81408688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210071491.3A Active CN114456191B (zh) | 2022-03-29 | 2022-03-29 | 山药地上部分生育酚衍生物的提取方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114456191B (zh) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105497413A (zh) * | 2015-12-21 | 2016-04-20 | 新乡医学院 | 山药地上部分提取物及其制备方法和应用 |
CN107281255B (zh) * | 2017-05-23 | 2020-10-09 | 新乡医学院 | 刺槐叶活性部位及其制备方法和应用 |
CN109771483B (zh) * | 2019-03-18 | 2021-11-02 | 泉州师范学院 | 一种从水辣蓼中提取高活性α-葡萄糖苷酶抑制剂的方法 |
-
2022
- 2022-03-29 CN CN202210071491.3A patent/CN114456191B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN114456191A (zh) | 2022-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110627861B (zh) | 一种知母甾体皂苷化合物及其制备方法和应用 | |
CN106008502A (zh) | 马齿苋中新骨架生物碱化合物及其提取分离方法 | |
Geng et al. | Meyeniihydantoins A–C, three novel hydantoin derivatives from the roots of Lepidium meyenii Walp. | |
CN104490894B (zh) | 阔叶丰花草三萜化合物的制备方法及其在制备糖苷酶抑制剂药物中的应用 | |
Wang et al. | Antioxidant, anti-inflammatory, and antidiabetic activities of bioactive compounds from the fruits of Livistona chinensis based on network pharmacology prediction | |
CN102180850A (zh) | 一类麦冬中高异黄酮类化合物及制备方法和用途 | |
CN111789873B (zh) | 高含量沙棘三萜酸提取物的提取方法 | |
Xiang et al. | Screening, characterization of trace α-glucosidase inhibitors from the root of Pueraria lobata and evaluation of their hypoglycemic activity | |
CN114456191B (zh) | 山药地上部分生育酚衍生物的提取方法和应用 | |
CN111747881A (zh) | 两种具有α-葡萄糖苷酶抑制作用的异戊烯基取代吲哚生物碱及其制备方法和应用 | |
Luo et al. | Alkaloids, sesquiterpenoids and hybrids of terpenoid with p-hydroxycinnamic acid from Ganoderma sinensis and their biological evaluation | |
CN106565444B (zh) | 山药地上部分菲类化合物的提取方法及应用 | |
CN114262294B (zh) | 一种苯基异喹啉生物碱化合物及其制备方法与应用 | |
Qin et al. | (±)-Corysaxicolaine A: a pair of antitumor enantiomeric alkaloid dimers from Corydalis saxicola | |
Wu et al. | Three new acylphloroglucinol glucosides from the roots of Lysidice rhodostegia and their antioxidant activities | |
CN113278026B (zh) | 一种具有抗肿瘤活性的苦木素类化合物及其制备方法和应用 | |
CN113004299A (zh) | 山竹皮中具有降低餐后血糖的呫吨酮类化合物及其提取方法和应用 | |
CN106565811B (zh) | 山药地上部分降血糖有效成分的提取方法及应用 | |
CN114014899B (zh) | 一种抗癌化合物的制备方法 | |
CN109206392B (zh) | 一种香豆素类化合物及其制备方法与应用 | |
CN101333242B (zh) | 一种新的三萜皂苷类抗肿瘤化合物 | |
CN114177164B (zh) | 白花败酱蒽醇i的制备方法及其应用 | |
CN113912657B (zh) | 马齿苋中三种吲哚类生物碱及其提取分离方法与用途 | |
CN114409521B (zh) | 共生真菌Paraconiothyrium brasiliense提取的化合物及其应用 | |
CN112538100B (zh) | 一种从黄柏中提取的具有抗炎活性的异喹啉生物碱苷类化合物及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |